Jefferies Maintains Buy Rating and $110 Price Target for BridgeBio

Jefferies has reiterated a Buy rating on BridgeBio Pharma (BBIO) with a $110 price target. The firm cites high confidence in the regulatory approval of the lead drug candidate, BBP-418. This endorsement arrives as the company prepares for a PDUFA date of November 27, 2026, for the treatment of Limb-Girdle Muscular Dystrophy type 2I/R9 (LGMD2I/R9).

"Jefferies maintains over 90% conviction in full approval for BBP-418 by its November 27, 2026, PDUFA date," according to an analyst report regarding the rating.

Clinical Progress and Cardiac Benefits

The analyst outlook is supported by recent Phase III trial data for BBP-418. The drug targets a rare genetic muscle disease and has demonstrated physiological improvements beyond standard mobility markers. Clinical analyses show patients receiving the treatment experienced cardiac benefits, specifically in troponin levels and Left Ventricular Ejection Fraction (LVEF), which is a metric for measuring how effectively the heart pumps blood.

Financial Position and Market Performance

BridgeBio’s financial profile supports this analyst outlook. The company reported a 94% gross profit margin, reflecting the nature of its specialized pharmaceutical pipeline. Over the last twelve months, the company recorded a 202% surge in revenue as it transitions toward the potential commercialization of its late-stage assets.

What Is at Stake for Shareholders

The upcoming PDUFA (Prescription Drug User Fee Act) date is a milestone for BridgeBio. For investors, the regulatory decision on November 27, 2026, is a binary event that will determine the commercial viability of BBP-418. FDA approval would validate the firm's platform for treating rare diseases. The current analyst target of $110 implies a premium over recent trading levels. Market participants are focused on whether the company can maintain its current margin profile while managing the operational costs associated with a full-scale product launch.